# NAD and the Brain in the Research Literature | NAD+ > NAD and the brain: what the research shows — the NADPARK cerebral-NAD+ trial, the NR cognition study in mild cognitive impairment, and the IV NAD+ substance-use work. NAD+ neuro digest. The neuro slice of the NAD+ record: a precursor trial that raised cerebral NAD+, a cognition trial that did not move scores, and the IV work in substance-use disorder — each tagged by evidence strength. ## The short version This page covers NAD and the brain. NAD+ (the cell's energy-handling helper molecule) is needed by brain cells too, and its decline is one proposed link to age-related mitochondrial trouble in the brain. The standout finding: an oral precursor (NR) raised NAD+ *measured inside the brain* in Parkinson's patients. But a separate trial showed raising NAD+ did not improve memory scores in people with mild cognitive impairment. So NAD+ reaches the brain — whether that helps thinking is still unproven. Everything here is research, not treatment. ## Why the brain is an NAD+ target Neurons are metabolically demanding, and NAD+ is the coenzyme their mitochondria depend on for ATP [5]. Declining NAD+ has been proposed to drive *pseudohypoxia* — a breakdown in nuclear-mitochondrial communication that mimics low oxygen even when oxygen is fine — linking falling NAD+ to mitochondrial dysfunction in aging tissue, including the brain [5]. CD38, the NAD+-consuming ectoenzyme that rises with age and inflammation, further drains the pool [2][11]. That mechanistic chain — low NAD+, impaired mitochondria, neuronal stress — is why neurodegeneration researchers have tested whether raising NAD+ helps. The chain is plausible; the human outcome data are thin and mixed. The brain also raised a specific empirical doubt that had to be answered before any neuro claim could stand: does an oral precursor actually move NAD+ *inside the brain*, behind the blood-brain barrier, or only in blood? Raising whole-blood NAD+ is well established [3][4], but blood is not brain. That question is what makes the cerebral-NAD+ measurement below the pivotal result in this module — it is the difference between a systemic biomarker and a central one. ## The NADPARK trial: a precursor raised cerebral NAD+ The clearest brain result in this record is anatomical, not clinical. In the NADPARK study — a randomized, double-blind, placebo-controlled trial in Parkinson's disease patients — oral NR at 1000 mg/day for 30 days raised *cerebral* NAD+, measured non-invasively by 31P magnetic resonance spectroscopy, and shifted the cerebrospinal-fluid metabolome in a direction consistent with enhanced mitochondrial function, alongside a favorable trend in clinical symptom scores [7] [CITATION-CONFIRMED]. This matters because it shows an oral precursor can move NAD+ in the brain itself, not just in blood — answering a real mechanistic doubt. It does not, by itself, establish a clinical benefit. ## The cognition gap: raising NAD+ did not improve scores in MCI The counterweight is just as important. In a randomized placebo-controlled trial in older adults with mild cognitive impairment, NR at 1 g/day for 10 weeks raised blood NAD+ 2.6-fold versus baseline and was well tolerated — but did not significantly improve performance on the Montreal Cognitive Assessment or related neurocognitive metrics [14] [GAP]. The implication is pointed: NAD+ elevation alone may be insufficient for cognitive improvement in MCI. This is the central honest finding of the neuro module — the biomarker moved, the cognition score did not. Marketed "brain" claims tend to cite the first kind of result and omit the second. ## IV NAD+ in substance-use disorder The brain literature also includes intravenous work in addiction. In a series of 50 treatment-resistant substance-use-disorder patients, IV NAD+ infusions combined with enkephalinase inhibition were associated with statistically significant reductions in craving (p = 1.06 × 10⁻⁹), anxiety (p = 5.49 × 10⁻⁷) and depression (p = 1.76 × 10⁻⁴), and 100% of urine samples in a 40-patient subset tested negative for illicit substances midway through treatment [13]. A narrative review documents historical addiction protocols dating to a 1961 case series of 104+ patients using 500-1000 mg IV NAD+ daily, while the same authors stress that IV NAD+ remains unapproved by the FDA and call for rigorous randomized trials [8]. This is preliminary, uncontrolled signal — promising to its authors, unproven by modern standards. See [IV NAD therapy](/iv-nad-therapy) for the route's full evidence picture. ## Reading the neuro evidence honestly Put the three brain findings side by side and the shape is clear. A precursor can raise NAD+ in the brain [7] — a real and non-trivial result. Raising it did not improve cognition in mild cognitive impairment over 10 weeks [14] — an equally real null. And the IV addiction work, while striking in its reported effect sizes [13], is uncontrolled and its authors call it unproven [8]. The plausible mechanism is intact; the clinical payoff is unconfirmed. This is the gap most "NAD+ for the brain" marketing papers over. The honest summary is not "NAD+ helps the brain" and not "NAD+ does nothing" — it is that NAD+ elevation reaches the brain but has not yet been shown to change a cognitive endpoint, and that the most dramatic neuro claims rest on the weakest study designs. The next chapter is larger, longer, controlled trials; this digest reports what the current ones measured, nothing more. ## Does NAD make you look younger? Tissue NAD+ falls with age, and restoring it improved healthspan markers in rodents — but most of that anti-aging data come from animals and may not extrapolate to people [2][5]. No human trial shows NAD+ or its precursors reverse visible aging, and a 2025 review concluded human efficacy data remain limited [1]. The brain biomarker can move [7]; the cognitive and cosmetic outcomes are not established. --- A build-log reading of the NAD+ literature, traced from salvage pathway to brain — the coenzyme kept distinct from its NMN and NR precursors, the oral trials kept apart from the rapidly-cleared IV route, and the contested NMN supplement status logged as filed; no clinic compiles behind this console and nothing here is dosed, compounded, prescribed, or sold.